Related content

Immunotherapy for metastatic prostate cancer: where are we at with sipuleucel-T?

By Lü Chen   Williams Andrew K   Chalasani Venu   Martínez Carlos H   Chin Joseph  

Expert Opinion on Biological Therapy, Vol. 11, Iss. 1, 2011-01 ,pp. : 99-108

Informa Healthcare

Access to resources Recommend Favorite

Immunoregulatory T cells in cancer immunotherapy

By Morse Michael A   Clay Timothy M   Mosca Paul   Lyerly H Kim  

Expert Opinion on Biological Therapy, Vol. 2, Iss. 8, 2002-12 ,pp. : 827-834

Informa Healthcare

Access to resources Recommend Favorite

Recent clinical development of dendritic cell-based immunotherapy for prostate cancer

By Rini Brian  

Expert Opinion on Biological Therapy, Vol. 4, Iss. 11, 2004-11 ,pp. : 1729-1734

Informa Healthcare

Access to resources Recommend Favorite

2-5A Ligands - A New Concept for the Treatment of Prostate Cancer

By Cramer Hagen   Okicki James   Rho Taikyun   Wang Xinning   Silverman Robert   Heston Warren  

Nucleosides, Nucleotides & Nucleic Acids, Vol. 26, Iss. 10-12, 2007-10 ,pp. : 1471-1477

Taylor & Francis Ltd

Access to resources Recommend Favorite

Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge^®)

By Harzstark Andrea L   Small Eric J  

Expert Opinion on Biological Therapy, Vol. 7, Iss. 8, 2007-08 ,pp. : 1275-1280

Informa Healthcare

Access to resources Recommend Favorite